The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in Richter’s transformation
A lack of effective treatment options exists for patients with Richter’s transformation (RT). Tamar Tadmor, MD, Bnai Zion Medical Center, Haifa, Israel, discusses a Phase II non-randomized trial that investigated the efficacy of a triplet regimen of obinutuzumab, ibrutinib, and venetoclax in patients with RT (NCT04939363). The findings suggest that this chemotherapy-free regimen with a rapid venetoclax ramp-up may be a useful induction strategy prior to allogeneic stem cell transplantation (alloSCT) or CAR T-cell therapy in this patient population. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Grant or Consultations: Abbvie, Astra Zeneca, Roche, Janssen, Novartis, Takeda, Sanofi.
